1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Lung Disease - Pipeline Review, H1 2014

Lung Disease - Pipeline Review, H1 2014

  • March 2014
  • -
  • Global Markets Direct
  • -
  • 55 pages

Lung Disease - Pipeline Review, H1 2014

Summary

Global Markets Direct’s, ‘Lung Disease - Pipeline Review, H1 2014’, provides an overview of the Lung Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Lung Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Lung Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Lung Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Lung Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Lung Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Lung Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Lung Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Lung Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Lung Disease - Pipeline Review, H1 2014
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Lung Disease Overview 7
Therapeutics Development 8
Pipeline Products for Lung Disease - Overview 8
Pipeline Products for Lung Disease - Comparative Analysis 9
Lung Disease - Therapeutics under Development by Companies 10
Lung Disease - Therapeutics under Investigation by Universities/Institutes 12
Lung Disease - Pipeline Products Glance 13
Clinical Stage Products 13
Early Stage Products 14
Lung Disease - Products under Development by Companies 15
Lung Disease - Products under Investigation by Universities/Institutes 16
Lung Disease - Companies Involved in Therapeutics Development 17
Ablynx NV 17
Vectura Group plc 18
Pharmaxis Limited 19
AGI Therapeutics plc 20
Nostrum Pharmaceuticals, LLC 21
PharmaIN Corporation 22
Paranta Biosciences Limited 23
Serendex Pharmaceuticals A/S 24
Lung Disease - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Target 26
Assessment by Mechanism of Action 28
Assessment by Route of Administration 30
Assessment by Molecule Type 32
Drug Profiles 34
cladribine - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
sargramostim - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
VR-461 - Drug Profile 36
Product Description 36
Mechanism of Action 36
RandD Progress 36
PXS-4206 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
AGI-350 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
dapsone - Drug Profile 39
Product Description 39
Mechanism of Action 39
RandD Progress 39
Retinoic Acid Receptor Agonists - Drug Profile 40
Product Description 40
Mechanism of Action 40
RandD Progress 40
Recombinant Human Follistatin - Drug Profile 41
Product Description 41
Mechanism of Action 41
RandD Progress 41
PGC-VIP - Drug Profile 42
Product Description 42
Mechanism of Action 42
RandD Progress 42
Small Molecules to Inhibit Alpha-1 Antitrypsin Polymerization for Lung And Liver Diseases - Drug Profile 43
Product Description 43
Mechanism of Action 43
RandD Progress 43
Nanobody 1 For Pulmonary Disease - Drug Profile 44
Product Description 44
Mechanism of Action 44
RandD Progress 44
Nanobody 2 For Pulmonary Disease - Drug Profile 45
Product Description 45
Mechanism of Action 45
RandD Progress 45
Ornithine-Substituted ADP-Ribosyl HNP-1 - Drug Profile 46
Product Description 46
Mechanism of Action 46
RandD Progress 46
Ornithine-HNP-1 - Drug Profile 47
Product Description 47
Mechanism of Action 47
RandD Progress 47
Lung Disease - Dormant Projects 48
Lung Disease - Product Development Milestones 49
Featured News and Press Releases 49
Oct 15, 2013: Insmed Completes Enrollment of Phase 2 Clinical Trial of ARIKACE to Treat Nontuberculous Mycobacteria Lung Disease in U.S. and Canada 49
Jun 27, 2012: Researchers Provide Further Rationale For Proteo's Elafin Treatment In Newborn Infants 50
Mar 05, 2012: Medistem To Begin Clinical Trials Using ERC Stem Cells For Renal, Lung And Peripheral Artery Disease 51
Jan 02, 2012: Commonly Used Blood Pressure Drug Prevents Smoking-related Lung Damage In Mice 51
Appendix 54
Methodology 54
Coverage 54
Secondary Research 54
Primary Research 54
Expert Panel Validation 54
Contact Us 55
Disclaimer 55

List of Tables

Number of Products under Development for Lung Disease, H1 2014 8
Number of Products under Development for Lung Disease - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 11
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Development, H1 2014 14
Products under Development by Companies, H1 2014 15
Products under Investigation by Universities/Institutes, H1 2014 16
Lung Disease - Pipeline by Ablynx NV, H1 2014 17
Lung Disease - Pipeline by Vectura Group plc, H1 2014 18
Lung Disease - Pipeline by Pharmaxis Limited, H1 2014 19
Lung Disease - Pipeline by AGI Therapeutics plc, H1 2014 20
Lung Disease - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2014 21
Lung Disease - Pipeline by PharmaIN Corporation, H1 2014 22
Lung Disease - Pipeline by Paranta Biosciences Limited, H1 2014 23
Lung Disease - Pipeline by Serendex Pharmaceuticals A/S, H1 2014 24
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Stage and Target, H1 2014 27
Number of Products by Stage and Mechanism of Action, H1 2014 29
Number of Products by Stage and Route of Administration, H1 2014 31
Number of Products by Stage and Molecule Type, H1 2014 33
Lung Disease - Dormant Projects, H1 2014 48

List of Figures

Number of Products under Development for Lung Disease, H1 2014 8
Number of Products under Development for Lung Disease - Comparative Analysis, H1 2014 9
Number of Products under Development by Companies, H1 2014 10
Number of Products under Investigation by Universities/Institutes, H1 2014 12
Comparative Analysis by Clinical Stage Development, H1 2014 13
Comparative Analysis by Early Stage Products, H1 2014 14
Assessment by Monotherapy Products, H1 2014 25
Number of Products by Top 10 Target, H1 2014 26
Number of Products by Stage and Top 10 Target, H1 2014 27
Number of Products by Top 10 Mechanism of Action, H1 2014 28
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 29
Number of Products by Top 10 Route of Administration, H1 2014 30
Number of Products by Stage and Top 10 Route of Administration, H1 2014 31
Number of Products by Top 10 Molecule Type, H1 2014 32
Number of Products by Stage and Top 10 Molecule Type, H1 2014 33

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Bovine Respiratory Disease Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

Global Bovine Respiratory Disease Treatment Market: Overview Bovine respiratory disease (BRD) is a multifactorial and complex disorder caused due to combination of more than one microbial pathogens, impaired ...

Chronic Obstructive Pulmonary Disease (COPD) - Market Insights, Epidemiology and Market Forecast-2023

Chronic Obstructive Pulmonary Disease (COPD) - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Chronic Obstructive Pulmonary Disease (COPD) - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview ...

Allergic Rhinitis - Market Insights, Epidemiology and Market Forecast-2023

Allergic Rhinitis - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Allergic Rhinitis - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.